OPKO Health (NASDAQ:OPK) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

OPKO Health (NASDAQ:OPK) posted its earnings results on Thursday. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03, Zacks reports. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.67%. OPKO Health’s quarterly revenue was down 19.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.01 earnings per share.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO completed a second major asset sale of BioReference’s oncology assets and repositioned BioReference as a streamlined, regionally focused clinical lab with a national 4Kscore franchise, which management says positions the diagnostics business for sustained profitable growth in 2026.
• The company struck a collaboration with Regeneron (potentially >$1 billion in milestones plus royalties) and has an EBV vaccine partnership with Merck, providing non-dilutive funding and external development/commercial support for ModeX programs.
• ModeX clinical progress: MDX-2001 has dosed >25 patients with dose escalation showing tolerability and early efficacy signals, MDX-2004 (immune rejuvenator) and MDX-2003 (CD19/CD20 tetraspecific) are in/entering Phase 1, and multiple readouts/phase advances are expected through 2026.
• OPKO entered 2026 with a strong liquidity position (reported $369 million in cash/restricted cash) and an active buyback program (34.6M shares repurchased in 2025; ~$113M remaining authorization), which management is using alongside R&D investments.
• Financial headwinds remain as Q4 revenue declined to $148.5M (from $183.6M) after the divestiture, Q4 net loss was $31.3M, and full-year 2026 guidance implies heavy spending with total costs of $725M–$750M driven by increased R&D investment.

OPKO Health Price Performance

Shares of OPKO Health stock traded up $0.02 during trading on Thursday, hitting $1.20. 2,137,750 shares of the company’s stock traded hands, compared to its average volume of 2,457,783. The company has a market cap of $921.24 million, a PE ratio of -4.80 and a beta of 1.47. The firm’s fifty day moving average price is $1.27 and its 200 day moving average price is $1.36. OPKO Health has a twelve month low of $1.11 and a twelve month high of $2.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.70 and a quick ratio of 3.32.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently modified their holdings of OPK. Virtu Financial LLC acquired a new stake in shares of OPKO Health in the 4th quarter valued at $145,000. EP Wealth Advisors LLC acquired a new stake in shares of OPKO Health during the fourth quarter worth approximately $37,000. XTX Topco Ltd bought a new position in shares of OPKO Health in the fourth quarter valued at approximately $432,000. Zacks Investment Management acquired a new position in shares of OPKO Health in the 4th quarter worth approximately $27,000. Finally, Quadrature Capital Ltd bought a new stake in OPKO Health during the 4th quarter worth approximately $116,000. Institutional investors own 64.63% of the company’s stock.

Analyst Ratings Changes

OPK has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. began coverage on OPKO Health in a research report on Thursday, November 20th. They set a “neutral” rating for the company. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Finally, Jefferies Financial Group restated a “hold” rating and issued a $1.60 price target (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $2.28.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.